TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
On November 17, 2025, Dr. Reddy’s Laboratories announced its participation in an investor conference organized by JM Financial, scheduled for November 21, 2025, in Mumbai. This meeting, which will be conducted in person, aims to engage with investor groups and provide insights into the company’s operations and strategies. The event is significant for stakeholders as it reflects the company’s proactive approach in maintaining transparency and fostering investor relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. The company is involved in manufacturing and marketing a wide range of pharmaceuticals in India and overseas, focusing on generic drugs and active pharmaceutical ingredients.
Average Trading Volume: 1,014,912
Technical Sentiment Signal: Hold
Current Market Cap: $11.71B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.